KALA BIO, Inc. (KALA) |
| 0.6901 -0.122 (-15.02%) 08-28 16:00 |
| Open: | 0.8848 |
| High: | 1.0929 |
| Low: | 0.5867 |
| Volume: | 2,411,364 |
| Market Cap: | 13(M) |
| PE Ratio: | -0.24 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.09 |
| Resistance 1: | 0.90 |
| Pivot price: | 0.84 |
| Support 1: | 0.59 |
| Support 2: | 0.49 |
| 52w High: | 1030 |
| 52w Low: | 0.5867 |
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Financials
| EPS | -9.390 |
| Book Value | 12.560 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -69.3 |
| Return on Equity (ttm) | -238.7 |
Company news
Fri, 28 Aug 2026
KALA BIO Faces Nasdaq Delisting Risk on Minimum Bid Price Failure - Minichart
Fri, 28 Aug 2026
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Wed, 19 Aug 2026
KALA BIO: Q2 Earnings Snapshot - KTVB
Wed, 19 Aug 2026
KALA BIO, Inc. Q2 2026: Net loss $(1.58M), EPS $(21.32) — 10-Q Summary - TradingView
Wed, 19 Aug 2026
KALA BIO (KALA) pivots to biotech AI with $229K on hand - Stock Titan
Fri, 14 Aug 2026
KALA BIO (KALA) delays June 30, 2026 Form 10-Q to finalize liquidity analysis - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
